Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

62 results about "LAG3" patented technology

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.

Anti-lag3 antibodies and antigen-binding fragments

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
Owner:MERCK SHARP & DOHME LLC

Application of ceramide synthase genes in regulating biosynthesis of ganoderma triterpenes

The invention provides application of ceramide synthase genes in regulating biosynthesis of ganoderma triterpenes. Ganoderma LAG2 and LAG3 genes are co-silenced by means of a gene silencing technologyto increase the biosynthesis quantity of the ganoderma triterpenes. Through an RNA interference means, an important genetic operation means for improving the biosynthesis of the ganoderma triterpenoids by co-silencing the ceramide synthase genes LAG2 and LAG3 is provided, and a theoretical basis for improving the biosynthesis of the ganoderma triterpenes by means of a genetic engineering technique is provided.
Owner:NANJING AGRICULTURAL UNIVERSITY

Anti-pd-1/lag3 bispecific antibodies

Provided herein are anti-PD-1 / LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
Owner:MERCK SHARP & DOHME BV +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products